Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Noodles & Company Fourth Quarter 2025 Earnings Call - Sales Momentum and Restaurant Closures Lift Margins and EBITDA
Noodles & Company closed 2025 having rebuilt core operations, lifted food quality, and leaned into a value-focused menu strategy that produced tangible sales and margin improvement. System-wide compar...
- System-wide comparable sales grew 6.6% in Q4 2025, with company-owned comps up 7.3% and franchise comps up 3.8%.
- Sales acceleration continued into 2026, with system-wide comparable sales over 9% and traffic up over 4% year-to-date in Q1 2026.
- Restaurant contribution margin expanded to 14.1% in Q4 2025, up 290 basis points year-over-year.
- +12 more takeaways
GCT Semiconductor Holding, Inc. Q4 2025 Earnings Call - Early 5G Commercialization with Validation from Gogo and a Major Satellite Licensing Deal
GCT says 2025 was the year it moved from lab to live. The company shipped more than 1,900 5G chipsets in Q4, supported a live Gogo air-to-ground 5G network using its silicon, and signed a licensing ag...
- GCT began commercial 5G shipments in Q4 2025, delivering over 1,900 chipsets for initial deployments and customer testing programs.
- Gogo launched a live broadband 5G air-to-ground service powered by GCT’s chipset, the first network operator deployment validating the platform in a demanding environment.
- GCT signed a licensing agreement with a major satellite communications provider to integrate GCT 4G/5G chipsets into user equipment, with shipments expected as early as H2 2026.
- +12 more takeaways
Precigen Q4 2025 Earnings Call - Papzimeos Launch Momentum Signals Rapid Revenue Ramp to >$18M in Q1
Precigen says the company has moved from R&D to a commercial biotech with the first-ever approved therapy for adult recurrent respiratory papillomatosis, PAPZIMEOS. After first shipments in November, ...
- PAPZIMEOS received full FDA approval in August 2025 and commercial shipments began in November 2025, producing $3.4 million in product revenue in Q4 2025.
- Management expects PAPZIMEOS product revenue to exceed $18 million in Q1 2026, and that figure excludes any non-product collaboration or service revenue.
- Precigen says it has completed a strategic transition from R&D-stage company to a revenue-generating commercial biotech driven by the PAPZIMEOS launch.
- +13 more takeaways
LogicMark Q4 2025 Earnings Call - Product-led revenue lift validates platform pivot and IP strategy
LogicMark closed 2025 with tangible commercial traction as product upgrades and new device mix drove double-digit revenue growth and healthier margins. Q4 revenue rose 36% to $3.1 million, full-year r...
- Q4 2025 revenue $3.1 million, up 36% year over year; full-year 2025 revenue $11.4 million, up 15% versus 2024.
- Gross margin improved to 69.8% in Q4 from 66.3% a year ago; full-year gross margin remained strong at 66.8%.
- Q4 gross profit rose 43% to $2.1 million; full-year gross profit was $7.6 million, up 15% year over year.
- +12 more takeaways
CytoSorbents Corporation Q4 & Full Year 2025 Earnings Call - FDA path narrowing as company targets cash-flow breakeven in H2 2026
CytoSorbents closed 2025 with modest top-line progress, strong gross margins, and an explicit path to cash flow breakeven in the second half of 2026. Core revenue rose 4% to $37.1 million, driven by i...
- Full year 2025 revenue was $37.1 million, up 4% year over year and flat on a constant currency basis.
- Core growth was led by international direct sales outside Germany, up 13% to $8.6 million, and distributor sales, up 11.4% to $16.5 million, which together represent about 68% of revenue.
- Germany sales fell 10% to $11.8 million, a near-term hit management attributes to a proactive commercial restructuring.
- +11 more takeaways
Tivic Health Q4 & FY 2025 Earnings Call - Full Pivot to TLR5 Immunotherapy with In-House Manufacturing
Tivic used 2025 to execute a decisive strategic pivot, exiting its consumer device business and concentrating solely on a TLR5 immunotherapy platform anchored by lead candidate Entolimod and next-gene...
- Tivic completed a strategic pivot in 2025, exiting the ClearUP device and suspending non-core neuromodulation programs to focus 100% on biotherapeutics based on a TLR5 platform.
- Lead assets are Entolimod and a next-generation candidate, Entolasta, positioned to protect bone marrow and GI tissue from radiation and chemotherapy damage, according to management.
- Management claims Entolimod can be used prophylactically and post-exposure, addressing both hematopoietic and gastrointestinal injury, differentiating it from current G-CSF therapies.
- +12 more takeaways
Winnebago Industries Second Quarter Fiscal 2026 Earnings Call - Motorhome Momentum Offsets Towable and Marine Softness, Guidance Intact
Winnebago delivered a cautious but constructive quarter. Consolidated revenue rose 6% year over year, driven by a 29% surge in the motorhome segment that more than offset a 9% decline in towables and ...
- Consolidated net revenues rose 6% year over year in Q2 fiscal 2026, led by the motorhome segment.
- Motorhome RV revenue jumped 29% in the quarter, driving volume leverage and a 270 basis point improvement in segment operating margin to 2.4% for Q2.
- Towable RV revenue declined 9%, pressured by a shift toward lower price point models and lower unit volumes, though selective pricing helped offset some pressure.
- +12 more takeaways
Elemental Royalty Corporation Q4 2025 Earnings Call - Merger and Tether backing turbocharge cash flow and introduce XAUT dividend
The newly merged Elemental Royalty reported a record year driven by the combination of Elemental, Altus and EMX. Pro forma 2025 revenue would have been about $87.2 million, adjusted EBITDA was $35 mil...
- Merger impact: The combination of Elemental, Altus and EMX materially enlarged the royalty base and cash flow profile, with pro forma 2025 revenue of about $87.2 million if merged on January 1.
- Record financials: Adjusted EBITDA of $35 million and operating cash flow of $34 million for the reported period, with management highlighting continued leverage as full-year GEOs run through the combined vehicle next year.
- Tether strategic investor: Tether and Tether Investments invested $100 million, now owning about 32% of the company, enabling Elemental to offer the first dividend option payable in XAUT (Tether gold token).
- +12 more takeaways
Epsilon Energy Year-End 2025 Earnings Call - Peak acquisition and Parkman development set the stage for multi-year production and EBITDA growth
Epsilon reported a banner 2025, with Adjusted EBITDA up 75% and production up 54% year-over-year, driven by development activity and the November closing of the Peak Companies acquisition. The deal im...
- Adjusted EBITDA rose 75% and total production increased 54% year-over-year in 2025.
- Epsilon closed the Peak Companies acquisition on November 14, 2025, adding Powder River Basin (PRB) assets, a local operating team, and over 100 net high-IRR drilling locations.
- Proved developed producing reserves grew 69% and total proved reserves increased 86% year-over-year, with total company reserves at 156 Bcfe, including ~78 Bcf from the PRB deal.
- +12 more takeaways
Paychex Q3 Fiscal 2026 Earnings Call - Paycor and AI Drive Acceleration, Q4 Flagged for Timing Headwinds
Paychex posted a strong Q3, with revenue up 20% to $1.8 billion and adjusted operating income up 22%, led by the Paycor acquisition and rapid deployment of AI capabilities. Management Solutions grew 2...
- Revenue grew 20% year over year to $1.8 billion in Q3 fiscal 2026, driven by the Paycor acquisition and organic momentum.
- Adjusted operating income rose 22% year over year; adjusted operating margin expanded about 80 basis points to 47.7% for the quarter.
- Management Solutions revenue increased 23% to $1.4 billion; Paycor accounted for roughly 19 percentage points of headline growth.
- +12 more takeaways